The Patent Finder

Therachon SAS

Also on record
Records under this name other than patents Therachon SAS holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 5 of 5 · Back to Therachon SAS

PatentTitleStatus Expires Confidence
US 10,294,289Soluble Fibroblast Growth Factor Receptor 3 (SFGFR3) Polypeptides and Uses Thereof
now held by Pfizer Inc.
In force
 · High confidence
In forceHigh confidence
US 11,021,528Soluble Fibroblast Growth Factor Receptor 3 (SFGFR3) Polypeptides and Uses Thereof
now held by Pfizer Inc.
Lapsed on the fee record
Ended Jun 1, 2025 · High confidence
Lapsed on the fee recordEnded Jun 1, 2025High confidence
15/541,993Soluble FGFR3 Decoys for Treating Skeletal Growth Disorders
now held by Pfizer Inc.
Abandoned
Abandoned Mar 2, 2020
AbandonedAbandoned Mar 2, 2020
16/649,208Treatment of Abnormal Visceral Fat Deposition Using Soluble Fibroblast Growth Factor Receptor 3 (SFGFR3) Polypeptides
now held by Pfizer Inc.
Abandoned
Abandoned Nov 4, 2022
AbandonedAbandoned Nov 4, 2022
16/796,666Soluble FGFR3 Decoys for Treating Skeletal Growth Disorders
now held by Pfizer Inc.
Abandoned
Abandoned Feb 21, 2024
AbandonedAbandoned Feb 21, 2024
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited